DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Isentress (Raltegravir) - Current Clinical Trials


Isentress Related Clinical Trials

Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients [Completed]

Study to Characterize the Pharmacokinetics of Raltegravir in the Gastrointestinal (GI) Tract of Healthy Male Volunteers [Completed]

The Effect of Rifapentine on Raltegravir [Completed]

Effect of Antacids on the Pharmacokinetics of Raltegravir [Completed]

Raltegravir Use as Nonoccupational Postexposure Prophylaxis (NPEP) in Men Who Have Sex With Men [Completed]

Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir [Completed]

Evaluation of Raltegravir During the Third Trimester of Pregnancy [Recruiting]

Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected Subjects [Completed]

The Influence of Raltegravir on Pravastatin Pharmacokinetics(GRAPPA) [Completed]

Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138) [Completed]

Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis [Recruiting]

Atripla to Raltegravir Switch Study for CNS Toxicity [Completed]

Pharmacokinetic Drug Interaction Study Between Raltegravir and Atorvastatin. [Completed]

A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247) [Completed]

Antiretroviral Therapy Intensification With Raltegravir or Addition of Hyper-immune Bovine Colostrum in HIV-1 Infected Patients With Suboptimal CD4+ T Cell Response [Completed]

Buprenorphine/Raltegravir Pharmacokinetic Interaction Study [Completed]

Pharmacokinetic Drug-drug Interaction Study Between RaltEgravir and CITALopram in Healthy Subjects (RECITAL). [Completed]

A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248) [Completed]

Kaletra-isentress Treatment Evaluation [Completed]

Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1 [Terminated]

Levels of Raltegravir in the Female Genital Tissue [Completed]

A Pilot Study to Characterize the Pharmacokinetics of Raltegravir in the Cervicovaginal Fluids of HIV-infected Women [Completed]

Raltegravir and Atazanavir Dosing Strategy Study [Completed]

Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART. [Completed]

Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid [Completed]

A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIV [Terminated]

Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load [Active, not recruiting]

A Two Way Cross Over Pharmacokinetic Interaction Study Between Raltegravir and Amlodipine in Healthy Volunteers [Completed]

The Influence of GINkGo Biloba on the Pharmacokinetics of the UGT Substrate raltEgraviR (GINGER) [Completed]

Raltegravir Therapy for Women With HIV and Fat Accumulation [Completed]

Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study [Recruiting]

Comparison of Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Adults [Recruiting]

Comparison of Concentration-time Course of Plasma and Intracellular Raltegravir in Healthy Volunteers [Completed]

Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents [Active, not recruiting]

Raltegravir Kaletra Pharmacokinetics [Completed]

Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir [Recruiting]

Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects [Completed]

Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients [Recruiting]

Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients [Completed]

Raltegravir as Early Therapy in African-Americans Living With HIV Study [Completed]

A Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy Subjects [Completed]

Raltegravir in the Swiss HIV Cohort Study [Recruiting]

Renal Transplantation and Raltegravir in HIV-Infected Patients [Active, not recruiting]

Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients With Previous Complete Viral Suppression [Completed]

Switch From Tenofovir to Raltegravir for Low Bone Mineral Density [Completed]

Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women [Withdrawn]

A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054) [Completed]

A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas [Active, not recruiting]

Pharmacokinetic and Safety Study of Raltegravir and Atazanavir in a Once Daily Dose Regimen in HIV-1 Infected Patients [Completed]

Measurement of Plasma and Intracellular Concentrations of Raltegravir [Recruiting]

A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects [Completed]

MK-0518 Intensification And HDAC Inhibition In Depletion Of Resting CD4+ T Cell HIV Infection [Terminated]

Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients [Completed]

Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis [Completed]

Drug Interaction Study Between Raltegravir And UK-453,061 [Completed]

Comparing Raltegravir Genital Tract Distribution in HIV-infected Men and Women [Completed]

Safety and Efficacy of Raltegravir+TDF+3TC in HBV/HIV Co-infected Patients [Not yet recruiting]

Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP) [Active, not recruiting]

Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy [Completed]

Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected Patients Failing Current Antiretroviral Therapies (0518-005)(COMPLETED) [Completed]

Pilot Study to Compare the Pharmacokinetics Parameters in Plasma and Intracellular of Raltegravir Administered Once a Day in Adult Patients Infected With HIV [Completed]

Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects [Completed]

Pilot Study of Raltegravir Switch to Resolve Tenofovir Induced Proteinuria [Completed]

RAltegravir Switch STudy: Effects on Endothelial Recovery [Recruiting]

Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection [Not yet recruiting]

Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy [Terminated]

Safety Study of Lopinavir/Ritonavir With Raltegravir in HIV-infected Patients [Completed]

Patient Preference, Sleep Quality, and Anxiety/Depression: A Comparison of Raltegravir and Efavirenz [Recruiting]

Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut [Completed]

Effects of Raltegravir (Isentress«) on Lipid and Carbohydrate Metabolism and Mitochondrial Function in Healthy Volunteers [Recruiting]

Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection [Active, not recruiting]

TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents Efavirenz and Raltegravir [Completed]

Dual Therapy With Raltegravir and Darunavir/Ritonavir in HIV Infected Patients. [Recruiting]

Pilot Study With Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Treatment Naive HIV-Infected Subjects [Active, not recruiting]

The Effect of Antacids on the Pharmacokinetics (PK) of Raltegravir in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-824) [Active, not recruiting]

Pilot Study of a Raltegravir Based NRTI Sparing Regimen [Completed]

Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023) [Approved for marketing]

Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors [Completed]

Addition of Raltegravir to Established Antiretroviral Suppressive Therapy [Active, not recruiting]

Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients [Recruiting]

Raltegravir Activity In Lymphoid Tissues [Withdrawn]

RAL-eve Study: Raltegravir Substitution Study [Completed]

Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy [Completed]

Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users [Recruiting]

Effects of Raltegravir Based Regimen on Platelet Reactivity, Platelet-monocyte Aggregation and Immune Activation [Enrolling by invitation]

A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055) [Completed]

A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily [Active, not recruiting]

Abacavir Pharmacokinetic Study in the Absence/Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected Subjects [Completed]

Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen [Completed]

Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women. [Completed]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017